Overview

Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies

Status:
RECRUITING
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the safety and efficacy of mRNA vaccine for the KRAS mutation malignant tumors.
Phase:
PHASE1
Details
Lead Sponsor:
Sichuan University
Collaborator:
West China Hospital
Treatments:
toripalimab